Sign up
Pharma Capital

Synairgen says its drug well tolerated in phase II trial

Richard Marsden, CEO of Synairgen plc (LON:SNG), tells Proactive the phase II trial showed that its drug for the sufferers of chronic obstructive pulmonary disease (COPD) has been well tolerated.

 “To show the drug was well tolerated was a very important step. In coming days or weeks we will put some further data out, which hopefully will be the biomarker data,” he said.


View full SNG profile View Profile

Synairgen making headway


Synairgen making headway

View All

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.